Apnimed Analyst Price Targets

Wall Street analyst price targets and consensus rating for Apnimed (APMD).

Price Target Range — 1 Quarters

Analyst Consensus — 4 Analysts

4Buy

Consensus RatingBuy# Analysts4Avg. Consensus PT$50Upside to Avg. PT+224.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 25, 2026	LifeSci Capital	Francois Brisebois	Initiate	Outperform	$50
Aug 25, 2026	Cantor Fitzgerald	Josh Schimmer	Initiate	Overweight	$60
Aug 25, 2026	Evercore ISI Group	Umer Raffat	Initiate	Outperform	—
Aug 25, 2026	B of A Securities	Jason Gerberry	Initiate	Buy	$41

Analyst Ratings News

PRO
LifeSci Capital Initiates Coverage On Apnimed with Outperform Rating, Announces Price Target of $50

LifeSci Capital analyst Francois Brisebois initiates coverage on Apnimed (NASDAQ:APMD) with a Outperform rating and announces Price Target of $50.

Benzinga Newsdesk

This Agomab Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Analysts change outlook on top names. See all rating changes, including upgrades/downgrades/initiations. Coverage initiated on various stocks.

Avi Kapoor

PRO
Cantor Fitzgerald Initiates Coverage On Apnimed with Overweight Rating, Announces Price Target of $60

Cantor Fitzgerald analyst Josh Schimmer initiates coverage on Apnimed (NASDAQ:APMD) with a Overweight rating and announces Price Target of $60.

Benzinga Newsdesk

PRO
Evercore ISI Group Initiates Coverage On Apnimed with Outperform Rating

Evercore ISI Group analyst Umer Raffat initiates coverage on Apnimed (NASDAQ:APMD) with a Outperform rating.

Benzinga Newsdesk

PRO
B of A Securities Initiates Coverage On Apnimed with Buy Rating, Announces Price Target of $41

B of A Securities analyst Jason Gerberry initiates coverage on Apnimed (NASDAQ:APMD) with a Buy rating and announces Price Target of $41.

Benzinga Newsdesk

Apnimed Inc

Apnimed Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
LifeSci Capital Initiates Coverage On Apnimed with Outperform Rating, Announces Price Target of $50

This Agomab Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

PRO
Cantor Fitzgerald Initiates Coverage On Apnimed with Overweight Rating, Announces Price Target of $60

PRO
Evercore ISI Group Initiates Coverage On Apnimed with Outperform Rating

PRO
B of A Securities Initiates Coverage On Apnimed with Buy Rating, Announces Price Target of $41

People Also Watch

People Also Watch

Apnimed Inc

Apnimed Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROLifeSci Capital Initiates Coverage On Apnimed with Outperform Rating, Announces Price Target of $50

This Agomab Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

PROCantor Fitzgerald Initiates Coverage On Apnimed with Overweight Rating, Announces Price Target of $60

PROEvercore ISI Group Initiates Coverage On Apnimed with Outperform Rating

PROB of A Securities Initiates Coverage On Apnimed with Buy Rating, Announces Price Target of $41

People Also Watch

People Also Watch

PRO
LifeSci Capital Initiates Coverage On Apnimed with Outperform Rating, Announces Price Target of $50

PRO
Cantor Fitzgerald Initiates Coverage On Apnimed with Overweight Rating, Announces Price Target of $60

PRO
Evercore ISI Group Initiates Coverage On Apnimed with Outperform Rating

PRO
B of A Securities Initiates Coverage On Apnimed with Buy Rating, Announces Price Target of $41